Long non-coding RNAs: potential new biomarkers for predicting tumor invasion and metastasis by unknown
REVIEW Open Access
Long non-coding RNAs: potential new
biomarkers for predicting tumor invasion
and metastasis
Chunyang Jiang1†, Xin Li2†, Hui Zhao1 and Huibin Liu3*
Abstract
Long non-coding RNAs (lncRNAs) play important roles in malignant neoplasia. Indeed, many hallmarks of cancer
define that the malignant phenotype of tumor cells are controlled by lncRNAs. Despite a growing number of
studies highlighting their importance in cancer, there has been no systematic review of metastasis-associated
lncRNAs in various cancer types. Accordingly, we focus on the key metastasis-related lncRNAs and outline their
expression status in cancer tissues by reviewing the previous stuides, in order to summarize the nowadays research
achivements for lncRNAs related to cancer metastasis. Medline, EMBASE, as well as PubMed databases were applied
to study lncRNAs which were tightly associated with tumor invasion and metastasis. Up to now, a substantial
number of lncRNAs have been found to have important biological functions. In this review, according to their various
features in cancer, lncRNAs were roughly divided into three categories: promoting tumor invasion and metastasis,
negative regulation of tumor metastasis and with dual regulatory roles. The present studies may establish the foundation
for both further research on the mechanisms of cancer progression and future lncRNA-based clinical applications.
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Background
The Encyclopedia of DNA Elements (ENCODE) project,
the functional annotation of all regulatory regions of the
human genome, has confirmed that 80 % of the genome
is transcribed into RNA but less than 2 % is translated
into proteins. Those RNA molecules that lack protein-
coding capability are collectively referred to as non-
coding RNA (NcRNA) [1–3]. These NcRNAs are divided
into housekeeping NcRNA and regulatory NcRNA [4],
and, according to their molecular size, the latter can be
subdivided into three major types: short NcRNA, mid-size
NcRNA, and Long non-coding RNAs (lncRNAs) [5].
This review focuses on lncRNAs—those longer than 200
nucleotides (nt). Numerous studies have demonstrated that
lncRNAs contribute to chromosome dosage-compensation,
imprinting, epigenetic regulation, cell cycle control, nuclear
and cytoplasmic trafficking, transcription, translation,
splicing, and cell differentiation among other functions [6].
Studies also suggest that lncRNA aberrant expression is
associated with numerous diseases including cancer. Cur-
rently, dozens of lncRNAs are implicated in the develop-
ment and progression of cancer [7, 8]; hence, they may
reveal novel mechanisms of transformation, tumor
growth, and metastasis, as well as present new targets for
cancer therapy.
Biological functions of lncRNAs
In the following sections, we will highlight the gene regula-
tory mechanisms and signaling pathways dependent on
lncRNAs. The majority of lncRNAs described were in-
volved in regulating the expression of protein-coding genes
in cis (affecting neighboring genes) or in trans (affecting
distant genes on different chromosomes) [6, 8]. LncRNAs
control transcription, translation, and protein function at
multiple levels. Various lncRNAs have been implicated in
the regulation of individual genes as well as gene expression
programs through epigenetic regulation or by altering the
basal transcriptional machinery. Specifically, lncRNAs can
(1) interfere with downstream gene expression by
* Correspondence: lhbrose2010@126.com
†Equal contributors
3Department of pharmacology, Affiliated Tumor Hospital of Xinjiang Medical
University, Urumqi 830011, People’s Republic of China
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Jiang et al. Molecular Cancer  (2016) 15:62 
DOI 10.1186/s12943-016-0545-z
transcription at the upstream promoter region of protein-
coding genes; (2) affect the expression of multiple down-
stream genes by inhibiting the activity of RNA polymerase
II or via chromatin remodeling and histone modification;
(3) disturb mRNA splicing patterns so as to produce differ-
ent splice variants by complementary binding with pre-
mRNAs; (4) modulate protein activity through direct bind-
ing; (5) function as scaffolds to form RNA-protein com-
plexes; (6) regulate the subcellular localization of specific
proteins; (7) serve as transcriptional precursors of small
RNAs that can also regulate gene expression [9]. Due to
this functional diversity, it is reasonable to speculate that
over- or underexpression of lncRNAs can compromise a
myriad of biological processes, thereby contributing to the
pathogenesis of disease.
In fact, there is now beyond doubt that lncRNAs are
of clinical importance, including for cancer biology and
treatment. Many lncRNAs exhibit altered expression
levels in cancer cells compared with healthy tissue of the
same origin [10, 11]. Utilizing comparative mammalian
genomics approach coupled with evolutionary analysis,
Khachane and Harrison identified a small population of
conserved long non-protein-coding RNAs (lncRNAs) in
the evolution, and these lncRNAs could play an import-
ant role in cancer pathomechanisms [12]. Here we will
highlight recent studies supporting the direct involve-
ment of individual lncRNA molecules in the invasion
and metastasis of various types of cancer.
LncRNAs in the invasion-metastasis cascade
Malignant tumors with infiltrative growth not only
continuously grow and spread locally in situ, but also
disseminate to other tissues through the lymphatic and
circulatory systems as well as the body cavity via a
process collectively referred to as tumor metastasis.
Metastasis is one of the most significant biological
characteristics of cancer and the leading cause of cancer-
related death. Overexpression of NcRNAs are implicated
in metastasis of human tumors, but most are shorter
NcRNAs like microRNAs (miRNAs) [13]. However, re-
cent studies have linked specific lncRNA gene mutations
with cancer, raising the possibility of lncRNA-based can-
cer diagnostics and therapy. Dozens of lncRNAs are now
widely believed to be involved in invasion and metastasis
[14]. Therefore, this review will focus primarily on emer-
ging mechanistic principles that underlie the nuclear
functions of lncRNAs in order to provide oncologists
with molecular insights that will help future research on
lncRNAs in cancer management.
LncRNAs promote tumor invasion and metastasis
For the few lncRNAs that are characterized at the func-
tional level, evidence is accumulating that they play piv-
otal roles in malignant diseases. Many features that
define the malignant cell phenotype are controlled by
lncRNAs, particularly the processes involved in metasta-
sis. Below we describe several lncRNAs implicated in the
etiopathology of malignant disorders, particularly those
that distinguish highly aggressive tumors from indolent
forms (summarized in Table 1).
HOTAIR
HOTAIR is a non-coding 2.2-kb RNA gene located down-
stream, in the antisense direction, of the gene encoding
homeobox C12 (HOXC12). The HOTAIR lncRNA acts as
a scaffold for histone modification complexes, allowing
them to coordinately interact with the histone modifiers
Polycomb Repressive Complex 2 (PRC2, a histone methyl-
transferase) and lysine-specific demethylase 1 (LSD1). In
turn, HOTAIR guides these proteins to specific genomic
regions and regulates gene expression through histone tail
methylation. In cancer cells, HOTAIR partners with PRC2
to induce genome-wide gene silencing. Enhanced expres-
sion of HOTAIR has been found in both primary and
metastatic lesions of multiple cancer types. In most cases,
elevated HOTAIR expression was correlated with metasta-
sis and poor prognosis [15]. As a cancer-associated
lncRNA, HOTAIR is a prospective biomarker of metasta-
sis and poor prognosis in a diverse group of cancers.
HOTAIR facilitates H3 lysine 27 methylation by PRC2 in
a fibroblast cell model (producing H3K27). In situ, this
pathway facilitated the invasion-metastasis cascade of
breast cancer by repressing the expression of hox transcrip-
tion factor protein D10 (homeobox D10 or HOXD10), pro-
gesterone receptor 1 (PRG1), cell adhesion molecules
protocadherins (PCDHs), and tumor angiogenesis-related
molecular ephrin receptors [16]. Recent studies have con-
firmed that HOTAIR expression levels differ substantially
between primary and metastasized breast cancer, and so
could be used as a prognostic marker [17].
HOTAIR is also frequently upregulated in oral squa-
mous cell carcinoma and nasopharyngeal carcinoma,
and overexpression is highly correlated with tumor me-
tastasis, clinical stage, and poor prognosis. Multiple lines
of evidence have established that HOTAIR was involved
in a large range of biological processes and diseases, par-
ticularly in cancer development and metastasis [18, 19].
HOTAIR expression is higher in gastric cancer tissues
than corresponding noncancerous tissues. Expression
level is significantly related to larger tumor size, ad-
vanced pathological TNM stage, and distant metastasis,
as well as shorter patient survival rate, particularly when
associated with lymph node metastasis. HOTAIR knock-
down efficiently inhibits cell proliferation and matrix
invasiveness in gastric cancer cells in vitro [20–23].
In 78 cases of esophageal squamous cell carcinoma
(ESCC) patients, almost all with high expression of
HOTAIR in tumor tissues (75/78, 96.15 %), expression
Jiang et al. Molecular Cancer  (2016) 15:62 Page 2 of 15
Table 1 LncRNAs with experimental data supporting the functions of promoting tumor invasion and metastasis
LncRNAs Source (Tissues and/or cells) Expression
in patients
Related genes Experimental data Function References
HOTAIR Breast cancer, OSCC, GC,
Nasopharyngeal carcinoma,
ESCC, HCC, NSCLC, EOC, PCa,
Colon cancer
Increased PRC2, LSD1, H3K4, H3K27,









MALAT1 Glioblastoma, Breast cancer,
Lung cancer, ESCC, Pancreatic
cancer, Kidney cancer,
Bladder cancer, PCa, CRC, GC
Increased WIF-1, N-Myc, JMJD1A,
ATM-CHK2 pathway, p21









stage, bad prognosis, inhibit
cell cycle and apoptosis
OG [39–57]
H19 GC, Ovarian cancer,
Endometrial cancer, Bladder
cancer, Epithelial cell








BANCR Malignant melanoma, Lung
cancer, Retinoblastoma, CRC











UCA1 TSCC, ESCC, CRC, Bladder
cancer, Malignant melanoma
Increased Promote cell proliferation,
increase invasion and
metastasis, inhibit cell cycle
and apoptosis, advanced
clinical stage, poor prognosis
OG [56, 71–74]








EAC Increased Increase tumorigenicity OG [78, 79]
PEG10 Esophageal cancer cells Increased Inhibit apoptosis, increase
invasion
OG [80]






SDMGC GC Increased TRIM16 Promotes invasion and
metastasis
OG [84]
GAPLINC GC Increased CD44 Promotes metastasis OG [85]
91H CRC Increased Promotes migration, invasion
and distant metastasis, poor
prognosis
OG [86]









XIST GSCs Increased miR-152 Promote cell proliferation,
invasion, metastasis
OG [91]
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level correlated with tumor metastasis, TNM staging,
and lower overall survival (OS) rate. The five-year sur-
vival rate of patients with positive HOTAIR expression
was greatly reduced compared with patients with nega-
tive expression. In vitro, HOTAIR facilitates ESCC cell
proliferation, colony formation, and migration [24],
while silencing of HOTAIR in ESCC KYSE30 cells re-
duced cell invasion and migration but enhances apop-
tosis rate [25]. In nude mice ESCC models, HOTAIR
promoted cell proliferation and tumor metastasis, while
knockout reduced the metastasis of ESCC cells [26].
HOTAIR may promote ESCC cell metastasis by inhibiting
the expression of Wnt inhibitory factor 1 (WIF-1), thereby
activating the Wnt/β-catenin signaling pathway [27].
Higher HOTAIR expression is also observed in hepato-
cellular carcinoma (HCC) tissues compared to adjacent
non-tumor tissues, and again expression level is associated
with lymphatic metastasis. Depletion of HOTAIR in the
HCC cell line Bel7402 reduces expression levels of matrix
metalloproteinase-9 (MMP-9) and vascular endothelial
growth factor (VEGF), and consequently attenuates cell
motility and metastasis [28]. Additionally, HOTAIR
impedes RNA binding motif 38 (RBM38) protein expres-
sion and initiates HCC cell invasion and migration [29].
HOTAIR expression level is also elevated in metastatic
lung cancer, and higher expression promotes tumor cell
motility and invasion [30]. Of 77 cases of non-small cell
lung cancer (NSCLC), 17 (22 %) exhibited high ex-
pression of HOTAIR, and these patients were more
frequently in an advanced stage with lymph node metas-
tasis or lymph-vascular invasion and had a shorter
disease-free interval. Moreover, NSCLC cases with brain
metastases showed higher HOTAIR levels [31]. Sup-
pressing cellular HOTAIR by targeted RNA interference
(RNAi) reduces NSCLC cell migration and invasion in
vitro and prevents the metastases of cells in vivo [32].
In cervical cancer samples, overexpression of HOTAIR
was associated with lymph node metastasis and shorter sur-
vival time [33]. Upregulation of HOTAIR can inhibit cell
apoptosis, block the cell cycle, and accelerate cell growth,
migration, and invasion, whereas HOTAIR downregulation
has the opposite effects. Facilitation of matrix invasion
and migration has been ascribed to HOTAIR-mediated
activation of VEGF, MMP-9, and genes associated with
Table 1 LncRNAs with experimental data supporting the functions of promoting tumor invasion and metastasis (Continued)












BCAR4 Breast cancer Increased SNIP1, PNUTS, CCL21 Promotes cell metastasis OG [95]























EBIC Cervical cancer EZH2, E-cadherin Promote invasion and
metastasis
OG [103]








Abbreviations: OSCC oral squamous cell carcinoma, GC gastric cancer, ESCC esophageal squamous cell carcinoma, HCC hepatocellular carcinoma, NSCLC non-small
cell lung cancer, EOC epithelial ovarian cancer, PCa prostate cancer, CRC colorectal cancer, TSCC tongue squamous cell carcinoma, BLBC basal-like breast cancer,
OSCC oral squamous cell carcinoma, EAC esophageal adenocarcinoma, GSCs glioblastoma stem cells, RCC renal cell carcinoma, OG oncogene
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epithelial-to-mesenchymal transition (EMT) [33] as well
as inhibition of p21 [34]. The expression level of HOTAIR
in endometrial cancer tissues is also higher than in normal
endometrial tissues and is correlated with tumor stage,
myometrium invasion, and lymph node metastasis. Reduc-
tion of HOTAIR level in endometrial cancer HEC-1A cells
restrained cell proliferation, migration, and invasion [35].
Enhanced expression of HOTAIR in epithelial ovarian
cancer (EOC) tissues was associated with clinical stage,
pathological classification, lymph node metastasis, reduced
OS, and shorter disease-free survival (DFS). Inhibition of
HOTAIR in EOC cell lines (SKOV3. Ip1, HO8910-PM,
and HEY-A8) in vitro depresses cell migration and inva-
sion. The pro-metastatic effects of HOTAIR are partially
mediated by the modulation of matrix metalloproteinases
(MMPs) and EMT-related genes activities [36].
Compared to castration-sensitive prostate cancer
(PCa) cells, HOTAIR expression is elevated in more ag-
gressive castration-resistant PCa cells. A targeted short
interfering transcript (siHOTAIR) reduced the viability
and clonality of castration-resistant PCa and induced cell
apoptosis and cycle arrest in vitro and in vivo [37].
Colon cancer is the most lethal archenteric cancer and
is a common cause of cancer-related death worldwide.
HOTAIR was overexpressed from 2- to nearly 1,600-fold
in the cancer tissues. According to a HOTAIR ex-
pression level of >5-fold compared to adjacent tissues,
120 patients were divided into a high expression group
(n = 40) and a low expression group (n = 80). Increased
HOTAIR expression was strongly associated with depth
of tumor invasion, lymph node metastasis, organ metas-
tasis, pathological differentiation, vascular invasion, and
tumor progression. Although the effect of HOTAIR on
cell proliferation was modest, upregulation facilitated
colon cancer initiation and progression [38].
MALAT1
Metastasis-associated lung adenocarcinoma transcript 1,
(MALAT1, also known as NEAT2) is an lncRNA evolu-
tionarily conserved across mammalian species, whereas
no homolog is present in non-mammalian species.
MALAT1 is involved in the formation of nuclear speckles,
which are thought to be important for the processing of
pre-mRNAs, and is further reported to be dysregulated in
numerous cancers [39].
For glioblastoma, it cannot be completely resected due
to its invasive characteristics, which makes it the most
radical brain tumor in adults. MALAT1 is associated with
EMT, which confers invasive capacity to malignant cells,
and the depletion of MALAT1 can reduce the migration
of glioblastoma cells. Furthermore, MALAT1 overexpres-
sion was reversed by WIF1-mediated attenuation of WNT
signaling, which in turn inhibits glioblastoma cell migra-
tion [40]. Conversely, MALAT1 upregulation induced by
N-Myc-activated JMJD1A gene expression enhances mi-
gration and invasion of glioblastoma cells [41].
In breast cancer cell lines MCF10a, MCF7, and MB231,
levels of MALAT1 were significantly decreased by treat-
ment with 100 nM 17β-Estradiol (E2), and the E2 treat-
ment affects breast tumor cells proliferation, migration and
invasion in an ERα -independent, but a dose-dependent
way by decreasing the MALAT-1 RNA level [42].
In lung cancer, MALAT1 was initially discovered as a
predictive biomarker for metastasis that induces the
expression of metastasis-associated genes. Depletion of
MALAT1 in the adenocarcinomic human alveolar basal
epithelial cell line A549 decreased cell migration,
increased apoptosis, and inhibited clonogenic growth.
Similarly, diminished MALAT1 expression impaired
tumor formation and growth in nude mice [43, 44].
Upregulation of MALAT1 was also highly correlated
with clinical stage, primary tumor size, and lymph node
metastasis of ESCC in vivo and in vitro [45]. In one
series, high MALAT1 expression was observed in 46.3 %
of ESCCs. Over-expression of MALAT1 was most
frequently in advanced stage tumor samples. MALAT1
affected cell growth through regulation of the ATM-
CHK2 pathway, allowing gene amplification in the
tumor progression period. Post-transcriptional silencing
of MALAT1 can reduce ESCC cell proliferation through
cell cycle block, and this may relate to suppression of
MALAT1-mediated upregulation of p21 and p27 as well as
inhibition of the cell cycle-associated transcription factor
B-MYB. In addition, knockdown of MALAT1 enhanced
resistance to ESCC cell invasion and metastasis [46].
MALAT1 expression was also higher in pancreatic tumor
specimens than in matched normal tissues and was upregu-
lated in seven pancreatic cancer cell lines [47]. Stable
knockout of MALAT1 prevents cell proliferation and mo-
tility, which is associated with G2/M arrest, enhanced apop-
tosis, disrupted EMT, and weakened cancer stem-like
properties in vitro, consistent with a putative oncogenic
role for MALAT1 in this usually fatal disease [47].
MALAT1 is upregulated in a number of urologic neo-
plasms. Higher MALAT1 expression was detected both in
clear cell renal cell carcinoma (ccRCC) tissues than in ad-
jacent non-tumor tissues and also in kidney cancer cells
than normal epithelial HK-2 cells. The ccRCC patients
with higher MALAT1 level more often had advanced clin-
ical features (such as greater tumor size, depth of tumor
invasion, and lymphatic invasion) and poor survival rate
[48]. MALAT1 is also upregulated in bladder cancer tis-
sues relative to matched non-cancerous tissue samples.
Knockout of MALAT1 in bladder cancer animal models
resulted in inhibition of malignant cell metastasis by redu-
cing Wnt signaling and thereby suppressing EMT [49, 50].
Overexpression of MALAT1 is observed in human
PCa tissues and cell lines and is closely associated with
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high patient Gleason score, prostate specific antigen
expression, clinical stage, and castration resistant PCa.
Silencing of MALAT1 abolished cell proliferation by
decelerating the G0/G1 phases of the cell cycle in
castration-resistant PCa cells. In castrated male nude
mice, siRNA-mediated silencing of MALAT1 delayed
tumor growth and inhibited PCa cell metastasis [51].
A functional study showed that the 3′ end of MALAT1
played an important role in metastasis of colon cancer
and colorectal cancer (CRC) [52]. MALAT1 is highly
induced in human CRC tissues in situ and often ac-
companies lymph node metastasis. Overexpression of
MALAT1 in mice using a lncRNA gain-of-function sys-
tem promoted CRC cell proliferation, invasion, and migra-
tion, and enhanced tumor growth and metastasis after
implantation. MALAT1 also exhibited positive effects on
CRC cell motility in vitro. The MALAT1 target gene
PRKA kinase anchor protein 9 (AKAP-9) was highly
expressed in both CRC cells and tissues with metastasis
potential. MALAT1 may thus promote invasion and me-
tastasis by targeting AKAP-9 [53]. Additionally, MALAT1
can release proto-oncogene PTBP2 by combining with the
tumor suppressor gene SFPQ, resulting in CRC metastasis
and disease progression [54]. Resveratrol, extracted from
the Chinese herbal medicine Polygonum cuspidatum, can
downregulate MALAT1 and attenuate Wnt/β-catenin sig-
naling, resulting in enhanced resistance to invasion and
metastasis of human CRC [55].
MALAT1 has also been implicated in post-transcriptional
gene regulation. In osteosarcoma (OS) MG-63 cells
treated with high-dose E2, MALAT1 bound and seques-
tered miR-9, thereby indirectly inducing genes normally
suppressed by miR-9. Decreasing the level of MALAT1 at-
tenuates EMT [56]. Furthermore, high expression of
MALAT1 was found exclusively in metastatic tissues
developed in lymph node, and knockout of MALAT1
inhibits melanoma cell migration in vitro [57].
MALAT2 is an lncRNA similar to MALAT1 in struc-
ture and function. In 146 cases of stage II/III gastric can-
cer (GC), increased expression of MALAT2 was positively
correlated with tumor stage and lymph node metastasis.
Ectopic expression of MALAT2 enhanced the motility of
the human GC cell line SGC-7901 in vitro, whereas silen-
cing of MALAT2 impairs tumor metastasis. MALAT2
may function by inducing EMT via the MEK/extracellular
signal-regulated kinase signaling pathway [58].
H19
H19 is a paternally imprinted gene located at chromo-
some 11p15.5 that was widely studied in cancer biology
even before lncRNAs had gained the attention of cancer
researchers. H19 is re-expressed during tumorigenesis
and promotes tumorigenic properties in multiple tissues,
including stomach, ovary, endometrium, and bladder.
Overexpression of H19 was believed to contribute to cell
proliferation and viability of GC cells through the upregu-
lation of miR-675, which resulted in the induction of the
angiogenesis inhibitor ISM1 and calcium-binding protein
CALN1 genes [21, 59–61]. The oncogenic properties of
H19 were strongly associated with antagonism of the
tumor suppressor miRNA let-7 and forced EMT mediated
by the non-histone chromosomal transcriptional regulator
HMGA2. Suppression of H19 using a targeted siRNA
could inactivate EMT [62]. MicroRNA let-7 reduces cell
growth and motility through post-transcriptional suppres-
sion of oncogenes. In ovarian and endometrial cancer, the
reciprocal functions of H19 and let-7 were associated with
let-7-mediated regulation of metastasis-related genes, in-
cluding c-Myc, HMGA2, and IGF2BP3 [63].
H19 level is elevated in bladder cancer tissues, and up-
regulated expression of H19 promoted cell motility and
metastasis of bladder cancer cells in vivo and in vitro.
H19-regulated malignant properties were associated with
enhancer of zeste homolog 2 (EZH2), the catalytic
subunit of PRC2. In this case, malignancy associated
with H19 appeared to be mediated by activation of Wnt/
β-catenin and E-cadherin signaling [64].
Moreover, H19 is overexpressed in epithelial cells and is
a target gene of fibroblast-derived growth factor HGF/SF,
a known regulator of epithelial −mesenchymal interac-
tions, implicating H19 upregulation in cell morphogenesis
and migration [65].
Bancr
The lncRNA BRAF-activated non-coding RNA (BANCR)
has been implicated in the initiation and progression of
malignant melanoma and lung cancer. BANCR overex-
pression is observed in melanoma cells and is significantly
associated with metastasis. Transfection of a targeted
BANCR siRNA resulted in diminished invasive and migra-
tory potential compared to cells transfected with control
siRNA [66]. In retinoblastoma tissues, high BANCR ex-
pression was correlated with tumor size and invasion of
choroid and optic nerve. Retinoblastoma cells transfected
with siBANCR exhibit reduced colony formation com-
pared to siControl-transfected cells in vitro [67].
In 60 cases of CRC, BANCR expression was upregulated
compared to corresponding normal specimens. Further-
more, high expression was correlated with poor prognoses.
Ectopic expression of BANCR was demonstrated in CRC
Caco-2 and HCT116 cells, and BANCR silencing inhibits
the migratory potential of these cell lines compared to
mock-transfected cells [68].
CCAT1 & CCAT2
Colon Cancer Associated Transcript 1 (CCAT1) is a
newly discovered lncRNA that has been characterized in
detail by RNA disruption assay (RDA), cDNA cloning,
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and rapid amplification of cDNA ends (RACE). It likely
participates in the genesis, development, invasion, and
metastasis of CRC, and so has garnered intense research
interest. Moreover, in a study of 66 HCC cases, expres-
sion levels of CCAT1 were dramatically higher in cancer
tissue than matching normal liver samples. Further re-
search supported the notion that CCAT1 could promote
invasion and metastasis of HCC by competitive combin-
ation with let-7 and inhibition of HMGA2 and c-Myc,
both endogenous target genes of let-7 [69]. Likewise,
CCAT1 expression is higher in primary GC tissues than
in adjacent normal mucosa. A chromatin immunopre-
cipitation assay showed that c-Myc could directly com-
bine with the E-box element of the CCAT1 promoter
region, thereby increasing CCAT1 expression. Conse-
quently, CCAT1 overexpression enhances the growth
and invasive capacities of GC cells [70].
CCAT2 was upregulated in two thirds of a large cohort
of primary breast cancer patients (997) and was a signifi-
cant risk factor for distant metastases [71]. CCAT2 was
also reported to be associated with colon cancer. It is
highly overexpressed in microsatellite-stable CRC and
promotes tumor growth, metastasis, and chromosomal in-
stability. Upregulated Myc expression and WNT signaling
induced by CCAT2 contributes to CRC pathogenesis [72].
UCA1
Urothelial carcinoma-associated 1 (UCA1), an oncofetal
gene involved in embryonic development and carcinogen-
esis, often exhibits extraordinarily high expression in
tumor tissues and cancer cells. In 94 cases of tongue
squamous cell carcinoma (TSCC), expression of UCA1
was much higher than in adjacent normal samples. As ex-
pected, the ectopic expression of UCA1 induced a marked
increase in lymph node metastasis [73].
Elevated levels of UCA1 are also found in ESCC tissues
and the immortalized esophageal epithelial cell line NE1
compared to respective controls. UCA1 overexpression
was often accompanied by tumor metastasis, suggesting
that this lncRNA could be clinically useful as a diagnostic
and prognostic indicator for ESCC patients [74].
In CRC tissues, high levels of UCA1 expression are
correlated with larger tumor volume, greater invasion
depth, less differentiated histology, and shorter survival.
These results implicate UCA1 in the pathogenesis of
CRC by enhancing the rates of cell growth, colonogenic
survival, and the invasive and migratory potential of
CRC cells [75]. Furthermore, under hypoxia, UCA1
levels are enhanced in bladder cancer cells compared to
controls, and this high level of UCA1 expression is sig-
nificantly correlated with greater tumor depth and apop-
tosis escape [76].
Expression of UCA1 is also higher in advanced stage
(III/IV) compared to early stage (I/II) melanoma. UCA1
upregulation was correlated with poor differentiation,
advanced lymph node classification, and metastasis of
melanoma cells, while invasive and migratory capacities
were remarkably diminished by UCA1 knockdown [57].
FOXCUT
FOXC1, a member of the Forkhead Box (FOX) family of
transcription factors, is a key regulator of tumor
occurrence and progression. The lncRNA-mRNA pair
FOXCUT − FOXC1 may be a new functional form. Recent
studies have demonstrated that high expression levels of
FOXCUT and FOXC1 are strongly associated with poor
prognosis in patients with base-like breast cancer (BLBC).
Conversely, inhibition of FOXCUT impaired the invasion
and migration capabilities of the breast cancer cell lines
MDA-MB-231 and MDA-MB-468 [77].
A recent report indicated that FOXCUT was also
more highly expressed in oral squamous cell carcinoma
(OSCC) tissues compared to matching adjacent normal
specimens and suggested a positive correlation with
FOXC1. Transfection of Tca8113 and SCC-9 OSCC cell
lines with a FOXCUT siRNA resulted in a substantially
reduced number of colonies and lower migratory poten-
tial [78]. Furthermore, FOXCUT overexpression level
was associated with tumor stage, metastasis, and post-
operative survival of patients with ESCC. FOXCUT
silencing in vitro using siRNA inhibited ESCC cell
growth, colony formation, and dissemination compared
to mock-transfected cells [79].
Other lncRNAs upregulated in tumor metastasis
Esophageal adenocarcinoma and esophageal squamous
cell carcinoma
Expression levels of the lncRNAs AFAP1-AS1, HNF1A-
AS1, and PEG10 are all markedly higher in malignant
esophageal adenocarcinoma (ECA) tissues than in nor-
mal para-carcinoma samples, and expression correlates
with cell motility, local infiltration depth, and vascular
invasion as well as with tumor staging and diffe-
rentiation level. On the contrary, knockdown of these
lncRNAs lead to diminished cell viability and increased
anoikis in EAC EC9706 and KYSE150 cells compared to
cells transfected with empty vector [80–82].
Increased levels of the lncRNAs SPRY4-IT1 and TUG1
are observed in ESCC tissues and several ESCC cell lines.
High SPRY4-IT1 expression level is positively correlated
with FIGO stage, histological tumor grade, and lymph
node metastasis. Suppression of the SPRY4-IT1 or TUG1
gene reduces invasive ability of ESCCs by blocking pro-
gression of the cell cycle [83, 84]. Khaitan et al. [85] found
that local infiltration depth of neuroblastoma was corre-
lated with dysregulated expression of SPRY4-IT1, leading
to repressed proliferation and extensive apoptosis. This ef-
fect was mediated by multiple MAPK signaling molecules,
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including Raf1, B-Raf, MEK1/2, TESK1, MARKK, and
MARK2. Thus, greater understanding of the underlying
mechanisms of SPRY4-IT1 in the molecular etiology of
ESCC could lead to major advances in lncRNA-directed
diagnostics and define new therapeutic targets against this
disease.
Gastric cancer and colorectal cancer
The lncRNA SDMGC (special for distant metastasis of
GC) is an indicator of poor survival rate whilst its target
gene TRIM16 is a positive prognostic factor in GC.
Inhibition of SDMGC by RNAi decreased invasion of
GC cells while suppression of TRIM16 has the opposite
effect [86]. The lncRNA GAPLINC (gastric adenocarcin-
oma predictive long intergenic noncoding RNA) is also
upregulated in GC patients, particularly with stage IV
and distant metastasis. In addition, GAPLINC can
function as a tumor promoter by upregulating CD44, a
cell surface glycoprotein known to facilitate tumor
metastasis [87].
Lately, it has been reported that lncRNAs regulated by
transforming growth factor (TGF)-β (ATB) could initiate
the invasion-metastasis cascade in CRC. Forced expres-
sion of ATB was closely related to bigger tumor volume,
depth of tumor invasion, vascular and lymphatic inva-
sion, as well as lymph node metastasis. In one study, pa-
tients with high ATB expression had strikingly shorter
overall survivals than those with low expression [88].
Furthermore, higher ATB expression was detected in
cancer patients with the transfer of blood-brone. Thus,
ATB may be involved in CRC progression and could de-
velop a promising indicator of worse prognosis [88].
Lung cancer
Lung cancer is the leading cause of cancer-related death
and remains a major public health problem worldwide.
Aside from HOTAIR and MALAT1, several other
lncRNAs are correlated with lung cancer metastasis.
LncRNA ZXF1 expression is markedly higher in lung
adenocarcinoma tissues compared to adjacent non-
cancerous lung tissues, and upregulated ZXF1 is
correlated with the presence and extent of lymph node
metastasis as well as tumor pathological stage. The
three-year OS rate of patients with higher ZXF1 expres-
sion is reduced compared to patients with lower ZXF1,
implying that high ZXF1 expression could be a marker
for poor prognosis. In vitro, knockdown of ZXF1 by
siRNA depressed the invasion and migration of A549
cells, whereas no remarkable effect was observed on cell
growth [89].
LncRNA GHSROS (GHSR opposite strand) is tran-
scribed from the antisense strand of the ghrelin receptor
gene growth hormone secretagogue receptor (GHSR).
Engineered overexpression of GHSROS stimulated cell
migration in the A549 and NCI-H1299 NSCLC cell
lines, but suppressed cell migration in the normal lung-
derived bronchoepithelial cell line Beas-2B, indicating
that GHSROS function may be dependent on the onco-
genic context [90].
Cancer-associated region long non-coding RNA
(CARLo-5) initially characterized in colon cancer was
identified a fresh lncRNA. Subsequent studies have doc-
umented marked upregulation of CARLo-5 in NSCLC
tissues compared to adjacent normal specimens. More-
over, patients with higher CARLo-5 expression levels
have considerably worse prognosis than those with low
expression. In vitro experiment, knockdown of CARLo-5
inhibited the proliferative activity, infiltration, and mi-
gration of NSCLC cell lines. Additionally, inhibition of
CARLo-5 could reverse EMT in a NSCLC cell line. In
summary, these results indicated that CARLo-5 may
serve as a new prognostic marker and a potential mo-
lecular target in treatment of NSCLC [91].
LncRNA AF118081, a new oncogenic lncRNA, is the
most highly overexpressed lncRNA in the transformed
bronchial epithelial cell line 16HBE-T as well as in lung
cancer specimens, while knockdown in 16HBE-T cells
inhibited proliferation and invasion. In agreement with the
results of in vitro assays, downregulation of AF118081 in a
xenograft mouse model suppresses tumor growth [92].
Glioblastoma multiforme (GBM)
Glioblastoma multiforme (GBM) is the most common
and aggressive primary brain tumor. The lncRNA XIST
(X-inactive specific transcript) is the master regulator of
X inactivation in mammals. XIST expression is upregu-
lated in glioma tissues and human glioblastoma stem
cells (GSCs), while knockdown of XIST reduced cell
proliferation, migration, and invasion, and induced
apoptosis. In vivo knockdown of XIST restrained tumor
growth and produced higher survival in nude mice.
XIST could mediate its oncogenic effect at least in part
by binding the tumor suppressor miR-152 [93].
Breast cancer
Commandeering of EMT regulatory pathways is a com-
mon mechanism whereby tumor cells depart from the
primary site to invade surrounding tissue and establish
distant metastases. Transforming growth factor beta
(TGF-β) signaling is a major decoy of EMT capable of
facilitating breast cancer metastasis, a process modulated
by the lncRNA HIT (HOXA antisense transcript in-
duced by TGF-β). HIT expression is dramatically in-
creased in the highly metastatic 4 T1 cell line, and
knockout of HIT in 4 T1 cells resulted in decreased cell
migration and invasion. Moreover, higher HIT expres-
sion was associated with more invasive human breast
carcinoma in patients [94].
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Linc-ROR is a large intergenic non-coding RNA of
about 2600 nt first described in induced pluripotent
stem cells (iPSCs) and as a regulator of embryonic stem
cell generation. Ectopic overexpression of linc-ROR en-
hanced breast cancer cell migration and invasion,
whereas silencing repressed tumor growth and lung me-
tastasis in vivo. Mechanistically, linc-ROR was associated
with miRNPs (ribonucleoprotein complexes containing
multiple miRNAs) and acted as a competitive endogen-
ous RNA to miR-205, a member of the miRNA-200
family frequently suppressed in high-grade tumors. Spe-
cifically, linc-ROR prevented the degradation of miR-205
target genes, including the EMT inducer ZEB2. Thus,
linc-ROR can operate as a chief regulator of EMT and
advance the progression and metastasis of breast cancer
through regulation of miRNAs [95].
The lncRNA Loc554202 gene at 9p21.3 does not con-
tain an open reading frame, but rather is transcribed from
four exons to create a spliced transcript of 2.2 kb.
Loc554202 is expressed at markedly higher levels in breast
cancer tissues than in normal controls and is associated
with advanced pathologic stage and greater tumor size.
Knockdown of Loc554202 depressed breast cancer cell
proliferation, induced apoptosis, and inhibited migration/
invasion in vitro as well as tumorigenesis in vivo [96].
LncRNA BCAR4 regulates a number of developmental
and tumorigenic processes by activating a non-canonical
Hedge-hog/GLI2 transcriptional program that promotes
cell migration. Increased BCAR4 level was correlated
with progressive mammary cancer, and targeting BCAR4
based on knockout of specific gene intensively sup-
pressed breast cancer spread in an animal model [97].
Urologic neoplasms
The lncRNA RCCRT1 is upregulated in renal cell carcin-
oma (RCC) compared to adjacent noncancerous tissues,
particularly in high-grade RCC tissues. Furthermore,
siRNA-induced depletion of RCCRT1 expression dimin-
ished migration and invasion in ACHN and A498 RCC
cell lines [98].
The lncRNA linc-UBC1a (up-regulated in bladder
cancer 1a) was aberrantly expressed in a large cohort (103
cases) of bladder cancer and correlated with poor progno-
sis. Knockdown of linc-UBC1a decelerated the growth
rate of bladder cancer cells, resulting in decreased tumor
growth and metastasis [99]. LncRNA linc-UBC1a is iden-
tical to the previously reported cancer-upregulated drug
resistant (CUDR) gene, which is known to play a pivotal
role in both embryonic development and bladder cancer
progression. Overexpression of UCA1a/CUDR elevated
proliferation, migration, and invasion of the bladder can-
cer cell line UM-UC-2 in vitro [100].
SChLAP1 is abundantly expressed in approximately
25 % of prostate cancers and aids in the discrimination
of aggressive tumors from indolent forms of the disease.
SChLAP1 can coordinate cancer cell invasion in vitro and
metastatic spread in vivo by impairing SNF5-mediated
regulation of gene expression and genomic binding [101].
Linc00963 is upregulated in androgen-dependent
LNCaP and androgen-independent C4-2 cell lines. Knock-
down of linc00963 attenuated the expression of EGFR and
the phosphorylation level of AKT even promoted apop-
tosis in C4-2 cells. These results suggested that Linc00963
prompted PCa transition from androgen-dependent to
androgen-independent and metastasis via the EGFR sig-
naling pathway [102].
The lncRNA PCGEM1 (Prostate cancer gene expres-
sion marker 1) has drawn increasing attention for its
important role in PCa. PCGEM1 polymorphisms may
contribute to PCa risk in Chinese men [103]. LncRNA
PCAT18 is specifically expressed in PCa, and PCAT18
silencing significantly inhibited PCa cell proliferation,
migration, and invasion, and triggered caspase 3/7 acti-
vation with no effect on non-neoplastic cells [104].
Female reproductive system tumors
LncRNA EBIC is another oncogenic lncRNA that regu-
lates metastasis of cervical cancer by binding to the tran-
scription repressor EZH2, thereby inhibiting E-cadherin
expression [105]. LncRNA HOST2 (human ovarian
cancer-specific transcript 2) is specifically overexpressed
in human ovarian cancer. HOST2 inhibited miRNA let-
7b function by reducing it bioavailability, leading to
post-transcriptional suppression of oncogenes that regu-
lated cell growth and motility [106]. The novel lincRNA
ZNF300P1 is frequently hypermethylated in multiple
ovarian cancer tissues and cell lines, and its expression
can influence cell polarity, motility, and adhesion, while
loss of expression may contribute to the metastatic po-
tential of ovarian cancer cells [107].
EOC tissues expressing E2 receptor alpha (ERα) also ex-
press higher levels of lncRNA TC0101441 compared to
ERα-negative tissues. Ectopic TC0101441 expression was
correlated with lymph node metastasis, while knockdown
impaired E2-induced EOC cell migration/invasion [108].
In aggregate, these findings implicate multiple lncRNAs
as possible diagnostic and therapeutic targets for aggres-
sive and metastatic cancers. In particular, the antitumor
effects of targeted knockdown highlight the potential of
lncRNA-based cancer therapies for patients at high risk
for metastasis, an outcome currently lacking effective che-
motherapeutic options.
LncRNAs involved in negative regulation of tumor
metastasis
Compared to oncogenic lncRNAs, few lncRNAs have
been confirmed as negative regulators of tumor invasion
and metastasis. Such anti-tumor lncRNAs are discussed
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below along with their correlated expression in tumors
(summarized in Table 2).
Lung cancer
In contrast to findings implicating BANCR in malignant
melanoma, lung cancer, and CRC metastasis, BANCR
levels are downregulated in NCI-H1688 and NCI-H446
lung carcinoma (LC) cell lines. When BANCR ex-
pression was strengthened by gain-of-function, tumor
growth depressed and vice versa. In addition, BANCR
was found to regulate LC proliferation and migration by
inactivation of p38 MAPK and JNK [109].
Prostate cancer
The lncRNA DRAIC was identified by RNA sequencing
(RNA-seq) and was found to be downregulated in the
progression from androgen-dependent to castration-
resistant PCa. Moreover, higher levels of DRAIC prevent
PCa invasion/migration by modulating androgen recep-
tor (AR) and FOXA1 expression, resulting in longer DFS
[14]. Similar to DRAIC, lncRNA PCAT29 acts as a
tumor suppressor via modulation of AR [110]. Thus,
these two lncRNAs may act as androgen-regulated
tumor suppressors in PCa.
Neurospongioma
The lncRNA TSLC1-AS1 is the antisense transcript of
tumor suppressor TSLC1. Its expression level is notably
lower in glioma tissues. In glioblastoma U87 cells, the
overexpression of TSLC1-AS1 upregulated TSLC1 and
inhibited cell proliferation, migration, and invasion,
while TSLC1-AS1 silencing has the opposite effects in
human neuroglioma SNB-19 cells. These results suggest
that TSLC1-AS1 may serve as a potential biomarker and
therapeutic target for glioma by interfering with TSLC1
expression [111]. The lncRNA ADAMTS9-AS2 is the
antisense transcript of tumor suppressor ADAMTS9.
ADAMTS9-AS2 is also a glioma suppressor as expres-
sion is correlated with lower tumor grade and better
prognosis. ADAMTS9-AS2 can modify malignant gli-
oma behavior through DNA methyltransferase-1 [112].
LncRNA CASC2 (cancer susceptibility candidate 2)
was originally described as a tumor suppressor gene in
endometrial and colorectal cancers. Low expression
levels have also been found in glioma tissues as well as
in U251 and U87 glioma cell lines. Overexpression of
CASC2 may hinder glioma progression by negative regu-
lation of miR-21 [113].
Head and neck squamous cell carcinoma
Application of next-generation RNA-seq revealed 2808
differentially expressed lncRNAs between 40 head and
neck squamous cell carcinoma and paired normal tissues.
The expression levels of lncRNA LCE5A-1 and KCTD6-3
were markedly lower in head and neck neoplasm tissues
and closely associated with the prognosis of patients. In
head neck squamous cell carcinoma cells, overexpression
of these two lncRNAs diminished cell growth and metas-
tasis by regulating EMT-related gene expression and inhi-
biting tumor stem cell functions [114].





Related genes Experimental data Function References
BANCR SCLC cell lines Decreased p38 MAPK, JNK Inhibit cell proliferation, decrease invasion
and metastasis
TS [107]
DRAIC; PCAT29 PCa Inhibit tumorigenicity and cell proliferation,






Decreased DNMT1, miR-21 Inhibit cell proliferation, decrease invasion
and metastasis, induce cell apoptosis
TS [109–111]
LCE5A-1; KCTD6-3 HNSCC Decreased EMT related
genes
Reduce cell proliferation and metastasis,
associated with the prognosis
TS [112]
GAS5; CADM1-AS1 RCC, ccRCC Decreased CADM1 Inhibit cell proliferation and cell growth,
decrease migration and invasion, induce
apoptosis and cell cycle arrest
TS [113, 114]
PTENP1 HCC Decreased PI3K/AKT
pathway
Inhibit tumor growth and cell proliferation,
cell invasion and migration, induce cell
autophagy and apoptosis
TS [115]
FENDRR GC Decreased FN1, MMP2,
MMP9
Inhibit cells invasion and migration TS [116]
ENST00000480739;
Meg3
PDAC, PNETs Decreased c-Met Prevent cell proliferation and delay cell
cycle, decrease cell migration, invasion and
metastasis
TS [117, 118]
Abbreviations: SCLC small cell lung cancer, PCa prostate cancer, HNSCC head and neck squamous cell carcinoma, RCC renal cell carcinoma, ccRCC clear cell renal
cell carcinoma, HCC hepatocellular carcinoma, GC gastric cancer, PDAC pancreatic ductal adenocarcinoma, PNETs pancreatic neuroendocrine tumors, TS tumor suppressor
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Renal cell carcinoma
The lncRNA growth-arrest-specific 5 (Gas5) sensitizes the
cell to apoptosis by regulating the activity of glucocorti-
coids in response to nutrient starvation. Gas5 has also
been linked to RCC as transcript levels are significantly re-
duced compared to unaffected normal renal tissues. Over-
expression of GAS5 in A498 cells induced apoptosis and
cell motility by acting as a transcription factor decoy for
steroid hormone receptors [115]. LncRNA CADM1-AS1
expression is downregulated in tumor tissues of 64
patients with ccRCC, the most common RCC subtype,
compared to adjacent non-tumor tissue. Furthermore,
CADM1-AS1 expression was positively correlated with
CADM1 mRNA expression in ccRCC specimens as well
as 786-O and ACHN renal carcinoma cells. Thus,
CADM1-AS1 was likely a ccRCC tumor suppressor that
regulates cell proliferation, apoptosis, and migration via
CADM1 [116].
Hepatocellular carcinoma and gastric cancer
The lncRNA PTENP1 modulates HCC cell behavior and
gene networks by miRNA regulation, including the
oncomirs miR-17, miR-19b, and miR-20a, as well as
through modulation of the PI3K/AKT pathway. Overex-
pression of PTENP1 mitigated tumor growth, sup-
pressed intratumoral cell proliferation, elicited apoptosis
and autophagy, and inhibited angiogenesis in an animal
model [117].
The lncRNA FENDRR controls the expression of
target genes epigenetically by binding to PRC2. Low
expression of FENDRR occured in GC cell lines and tis-
sues and was associated with poor prognosis. FENDER
overexpression suppressed invasion and migration in
GC cells in vitro by attenuating FN1 and MMP2/MMP9
gene expression [118].
Pancreatic cancer
LncRNA ENST00000480739 expression is dramatically
decreased in pancreatic ductal adenocarcinoma (PDAC),
which contributed to tumor metastasis and progression
by modulating HIF-1α. ENST00000480739 level was
negatively related to tumor node metastasis stage and
lymph node metastasis, indicating that it could be an in-
dependent prognostic factor of survival time in PDAC
patients following surgery [119]. Further, enhanced
ENST00000480739 expression in vitro inhibited PDAC
cell invasion [119].
The lncRNA maternally expressed gene 3 (Meg3) was
characterized as a tumor suppressor in pancreatic neuro-
endocrine tumor (PNET) cells. Overexpression of Meg3
in the insulin-secreting mouse PNET cell line MIN6 pre-
vented proliferation and delayed cell cycle progression.
Microarray studies have found that upregulated expres-
sion of Meg3 in MIN6 cells can attenuate the level of
the proto-oncogene c-Met and reduce cell migration
and invasion [120].
Dual function of lncRNAs
Only a few of the lncRNAs characterized to date have
shown dual tumor promotion and tumor suppressor func-
tions. As mentioned earlier, the 693-bp lncRNA BANCR
appears to both enhance and suppress metastatic potential.
BANCR expression was elevated in GC tissues compared
to matched non-cancerous tissue but downregulated in
113 NSCLC tumor tissues compared to match normal
samples. Moreover, the aberrant expression of BANCR was
positively associated with clinical stage, tumor depth,
lymph node metastasis, and distant metastasis, and was an
independent prognostic factor for GC/NSCLC in survival
analysis [121, 122]. H19 has also been found to have both
oncogenic and suppressive properties in different tumors
[123]. While several studies reported that H19 functioned
as an oncogenic lncRNA promoting tumor metastasis in
GC, ovarian cancer, endometrial cancer, and bladder can-
cer, other studies found that it inhibits tumor metastasis
via miR-675. Both H19 and H19-induced miR-675 expres-
sion level were significantly lower in metastatic PCa than
less aggressive PCa. The H19/miR-675 axis may have diag-
nostic and therapeutic potential for advanced PCa cases
[124]. Conversely, a miR-675 inhibitor or H19 siRNA
dramatically increases HCC cell migration and invasion via
the AKT/GSK-3β/Cdc25A signaling pathway [123]. The
dual functionality of certain lncRNAs may stem from dif-
ferential co-expression of other targets or tumor regulators
in specific cell types. The ‘off-target’ effects of lncRNAs via
indirect regulation or negative feedback look of gene-
expression would be one potential reason.
Conclusions and perspectives
At present, a large number of deregulated lncRNAs are
involved in proliferation, apoptosis and cell-cycle control
in the carcinogenesis, there is a growing list of lncRNAs
that contribute to the specific process of metastasis.
Some well-studied lncRNAs were demonstrated to be
differentially expressed in metastatic tumor foci. In less
than a decade of research on lncRNAs, as well as their
prominent role in the regulation of tumor progression,
have revealed the huge potential of the long non-coding
transcriptome for therapeutic intervention, both as
targets (when they are upregulated) and as drugs (when
they are downregulated or lost). Yet in spite of lncRNAs
becoming a research hotspot gradually, conceptual and
technical limitations have restricted our deeper under-
standing on their contributions to human malignant
tumors. Initially, the key factors for future development
are to improve computational approaches and databases
to distinguish potential functional and pathological links
between lncRNAs and tumor occurrence and metastasis.
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In addition, transporting ncRNAs only to potentially
cancerous cells is surely another main conundrum. It
may be more complicate matters considering the size of
lncRNAs when compared with miRNAs and siRNAs,
bringing greater challenges such as delivery and stability
to the target. However, nanoparticles and liposomes may
be reconstructed in order to achieve tumor-targeting
drug delivery, in an attempt to keep harmful side-effects
remained manageable. Lastly, few animal models have
been well developed to appraise the roles of lncRNAs in
vivo and even as we know, there is still no lncRNA that
enters clinical trials for the moment. The retardation of
animal assays and human clinical trials could greatly im-
pede the development and utilization of lncRNA-based
new drugs and this will be another focus and difficulty
of our research in the future.
Therefore, an absolute requirement is a more pro-
found awareness of lncRNA functions and mechanisms,
both in physiological and pathological circumstances. It
is now necessary to expand and reconstruct lncRNA-
enriched disease networks to develop new therapeutic
strategies, allowing to increase the specificity and to de-
crease the toxicity especially in cancer therapy, so that
lncRNA-based diagnostics and targeted therapeutics in
cancer and metastasis can safely and successfully enter
into regular clinical practice.
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